DEVELOPMNT OF CYCLODEXTRIN – BASED ORODISPERSIBLE TABLET OF AZITHROMYCIN: A NOVEL APPROACH TO IMPROVE DRUG DELEVERY

ABSTRACTAzithromycin is a broad-spectrum macrolide antibiotic with poor aqueous solubility and an intensely bitter taste, andconventional tablets are difficult to swallow for many paediatric and geriatric patients. The aim of this study was to develop andoptimize an orodispersible tablet (ODT) containing an azithromycin–β-cyclodextrin (β-CD) inclusion complex. Phase-solubilityanalysis was carried out with β-CD (0–10 mM), and a 1:1 molar inclusion complex was prepared by the kneading method andcharacterized by drug content, FTIR, DSC and SEM. Seven ODT batches (F1–F7) were prepared by direct compressionaccording to a 2² factorial design with three centre points, using crospovidone and sodium starch glycolate (SSG; 10–20 mg each) as factors and disintegration time and in-vitro drug release at 30 min as responses. Powder blends and tablets were evaluated by pharmacopoeial tests, and the optimized batch was stored for 3 months at 25 °C/60% RH and 40 °C/75% RH. Solubility increased linearly with β-CD concentration (AL-type, R² = 0.9997; about four-fold at 10 mM), and the complex contained 98.65 ± 0.32% drug. FTIR, DSC and SEM were consistent with complex formation. All batches showed acceptable flow properties and tablet quality. Batch F4 (crospovidone 20 mg, SSG 20 mg) was optimal, with a disintegration time of 25 ± 2 s, wetting time of 30 s, friability of 0.66%, drug content of 99.3% and 96.1% drug release in 30 min. Prediction errors were 2.91% for drug release and 17.45% for disintegration time. F4 showed no appreciable change in physical characteristics or drug content after 3 months under both storage conditions. Combining β-cyclodextrin complexation with superdisintegrant-based ODT technology therefore gave a rapidly disintegrating, mechanically acceptable and stable azithromycin tablet that is a promising patient-friendly dosage form for paediatric and geriatric use.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-18
DOI
https://doi.org/10.5281/zenodo.24332096
Primary Topic
Drug Solubulity and Delivery Systems
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

DEVELOPMNT OF CYCLODEXTRIN – BASED ORODISPERSIBLE TABLET OF AZITHROMYCIN: A NOVEL APPROACH TO IMPROVE DRUG DELEVERY

Rashmi Surve, Seema Paragannavar, Jyoti Hebbalkar, Pramod S. Gavade. et al.
Zenodo (CERN European Organization for Nuclear Research)
Drug Solubulity and Delivery Systems
article

DEVELOPMNT OF CYCLODEXTRIN – BASED ORODISPERSIBLE TABLET OF AZITHROMYCIN: A NOVEL APPROACH TO IMPROVE DRUG DELEVERY

Rashmi Surve, Seema Paragannavar, Jyoti Hebbalkar, Pramod S. Gavade., Karuna S. Chougule
article en

Abstract

ABSTRACTAzithromycin is a broad-spectrum macrolide antibiotic with poor aqueous solubility and an intensely bitter taste, andconventional tablets are difficult to swallow for many paediatric and geriatric patients. The aim of this study was to develop andoptimize an orodispersible tablet (ODT) containing an azithromycin–β-cyclodextrin (β-CD) inclusion complex. Phase-solubilityanalysis was carried out with β-CD (0–10 mM), and a 1:1 molar inclusion complex was prepared by the kneading method andcharacterized by drug content, FTIR, DSC and SEM. Seven ODT batches (F1–F7) were prepared by direct compressionaccording to a 2² factorial design with three centre points, using crospovidone and sodium starch glycolate (SSG; 10–20 mg each) as factors and disintegration time and in-vitro drug release at 30 min as responses. Powder blends and tablets were evaluated by pharmacopoeial tests, and the optimized batch was stored for 3 months at 25 °C/60% RH and 40 °C/75% RH. Solubility increased linearly with β-CD concentration (AL-type, R² = 0.9997; about four-fold at 10 mM), and the complex contained 98.65 ± 0.32% drug. FTIR, DSC and SEM were consistent with complex formation. All batches showed acceptable flow properties and tablet quality. Batch F4 (crospovidone 20 mg, SSG 20 mg) was optimal, with a disintegration time of 25 ± 2 s, wetting time of 30 s, friability of 0.66%, drug content of 99.3% and 96.1% drug release in 30 min. Prediction errors were 2.91% for drug release and 17.45% for disintegration time. F4 showed no appreciable change in physical characteristics or drug content after 3 months under both storage conditions. Combining β-cyclodextrin complexation with superdisintegrant-based ODT technology therefore gave a rapidly disintegrating, mechanically acceptable and stable azithromycin tablet that is a promising patient-friendly dosage form for paediatric and geriatric use.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Drug Solubulity and Delivery Systems
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon